The aim of the study was to verify if quantification of placental specific C19MC microRNAs in plasma exosomes would be able to differentiate during the early stages of gestation between patients subsequently developing pregnancy-related complications and women with the normal course of gestation and if this differentiation would lead to the improvement of the diagnostical potential. The retrospective study on singleton Caucasian pregnancies was performed within 6/2011-2/2019. The case control study, nested in a cohort, involved women that later developed GH (n = 57), PE (n = 43), FGR (n = 63), and 102 controls. Maternal plasma exosome profiling was performed with the selection of C19MC microRNAs with diagnostical potential only (miR-516b-5p, miR-517-5p, miR-518b, miR-520a-5p, miR-520h, and miR-525-5p) using real-time RT-PCR. The down-regulation of miR-517-5p, miR-520a-5p, and miR-525-5p was observed in patients with later occurrence of GH and PE. Maternal plasma exosomal profiling of selected C19MC microRNAs also revealed a novel down-regulated biomarker during the first trimester of gestation (miR-520a-5p) for women destinated to develop FGR. First trimester circulating plasma exosomes possess the identical C19MC microRNA expression profile as placental tissues derived from patients with GH, PE and FGR after labor. The predictive accuracy of first trimester C19MC microRNA screening (miR-517-5p, miR-520a-5p, and miR-525-5p) for the diagnosis of GH and PE was significantly higher in the case of expression profiling of maternal plasma exosomes compared to expression profiling of the whole maternal plasma samples.

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University 10000 Prague Czech Republic

Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University 14700 Prague Czech Republic

Zobrazit více v PubMed

Gunel T., Zeybek Y.G., Akçakaya P., Kalelioğlu I., Benian A., Ermis H., Aydınlı K. Serum microRNA expression in pregnancies with preeclampsia. Genet. Mol. Res. 2011;10:4034–4040. doi: 10.4238/2011.November.8.5. PubMed DOI

Yang Q., Lu J., Wang S., Li H., Ge Q., Lu Z. Application of next-generation sequencing technology to profile the circulating microRNAs in the serum of preeclampsia versus normal pregnant women. Clin. Chim. Acta. 2011;412:2167–2173. doi: 10.1016/j.cca.2011.07.029. PubMed DOI

Hromadnikova I., Kotlabova K., Doucha J., Dlouha K., Krofta L. Absolute and relative quantification of placenta-specific micrornas in maternal circulation with placental insufficiency-related complications. J. Mol. Diagn. 2012;14:160–167. doi: 10.1016/j.jmoldx.2011.11.003. PubMed DOI

Wu L., Zhou H., Lin H., Qi J., Zhu C., Gao Z., Wang H. Circulating microRNAs are elevated in plasma from severe preeclamptic pregnancies. Reproduction. 2012;143:389–397. doi: 10.1530/REP-11-0304. PubMed DOI

Hromadnikova I., Kotlabova K., Ondrackova M., Kestlerova A., Novotna V., Hympanova L., Doucha J., Krofta L. Circulating C19MC microRNAs in preeclampsia, gestational hypertension, and fetal growth restriction. Mediat. Inflamm. 2013;2013:186041. doi: 10.1155/2013/186041. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Hympanova L., Doucha J., Krofta L. First trimester screening of circulating C19MC microRNAs can predict subsequent onset of gestational hypertension. PLoS ONE. 2014;9:e113735. doi: 10.1371/journal.pone.0113735. PubMed DOI PMC

Ura B., Feriotto G., Monasta L., Bilel S., Zweyer M., Celeghini C. Potential role of circulating microRNAs as early markers of preeclampsia. Taiwan J. Obstet. Gynecol. 2014;53:232–234. doi: 10.1016/j.tjog.2014.03.001. PubMed DOI

Miura K., Higashijima A., Murakami Y., Tsukamoto O., Hasegawa Y., Abe S., Fuchi N., Miura S., Kaneuchi M., Masuzaki H. Circulating chromosome 19 miRNA cluster microRNAs in pregnant women with severe pre-eclampsia. J. Obstet. Gynaecol. Res. 2015;41:1526–1532. doi: 10.1111/jog.12749. PubMed DOI

Hromadnikova I., Kotlabova K., Ivankova K., Krofta L. First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR. PLoS ONE. 2017;12:e0171756. doi: 10.1371/journal.pone.0171756. PubMed DOI PMC

Wommack J.C., Trzeciakowski J.P., Miranda R.C., Stowe R.P., Ruiz R.J. Micro RNA clusters in maternal plasma are associated with preterm birth and infant outcomes. PLoS ONE. 2018;13:e0199029. doi: 10.1371/journal.pone.0199029. PubMed DOI PMC

Pillay P., Moodley K., Moodley J., Mackraj I. Placenta-derived exosomes: Potential biomarkers of preeclampsia. Int. J. Nanomed. 2017;12:8009–8023. doi: 10.2147/IJN.S142732. PubMed DOI PMC

Yu B., Zhang X., Li X. Exosomes derived from mesenchymal stem cells. Int. J. Mol. Sci. 2014;15:4142–4157. doi: 10.3390/ijms15034142. PubMed DOI PMC

Tomasetti M., Lee W., Santarelli L., Neuzil J. Exosome-derived microRNAs in cancer metabolism: Possible implications in cancer diagnostics and therapy. Exp. Mol. Med. 2017;49:e285. doi: 10.1038/emm.2016.153. PubMed DOI PMC

Zhou S., Abdouh M., Arena V., Arena M., Arena G.O. Reprogramming malignant cancer cells toward a benign phenotype following exposure to human embryonic stem cell microenvironment. PLoS ONE. 2017;12:e0169899. doi: 10.1371/journal.pone.0169899. PubMed DOI PMC

Théry C., Zitvogel L., Amigorena S. Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2002;2:569–579. doi: 10.1038/nri855. PubMed DOI

Kalra H., Adda C.G., Liem M., Ang C.S., Mechler A., Simpson R.J., Hulett M.D., Mathivanan S. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics. 2013;13:3354–3364. doi: 10.1002/pmic.201300282. PubMed DOI

Harding C.V., Heuser J.E., Stahl P.D. Exosomes: Looking back three decades and into the future. J. Cell Biol. 2013;200:367–371. doi: 10.1083/jcb.201212113. PubMed DOI PMC

Mitchell M.D., Peiris H.N., Kobayashi M., Koh Y.Q., Duncombe G., Illanes S.E., Rice G.E., Salomon C. Placental exosomes in normal and complicated pregnancy. Am. J. Obstet. Gynecol. 2015;213:S173–S181. doi: 10.1016/j.ajog.2015.07.001. PubMed DOI

Kalluri R. The biology and function of exosomes in cancer. J. Clin. Investig. 2016;126:1208–1215. doi: 10.1172/JCI81135. PubMed DOI PMC

Kalluri R., LeBleu V.S. Discovery of double-stranded genomic DNA in circulating exosomes. Cold Spring Harb. Symp. Quant. Biol. 2016;81:275–280. doi: 10.1101/sqb.2016.81.030932. PubMed DOI

Tkach M., Théry C. Communication by extracellular vesicles: Where we are and where we need to go. Cell. 2016;164:1226–1232. doi: 10.1016/j.cell.2016.01.043. PubMed DOI

Salomon C., Guanzon D., Scholz-Romero K., Longo S., Correa P., Illanes S.E., Rice G.E. Placental Exosomes as Early Biomarker of Preeclampsia: Potential Role of Exosomal MicroRNAs Across Gestation. J. Clin. Endocrinol. Metab. 2017;102:3182–3194. doi: 10.1210/jc.2017-00672. PubMed DOI

Batista I.A., Melo S.A. Exosomes and the Future of Immunotherapy in Pancreatic Cancer. Int. J. Mol. Sci. 2019;20:567. doi: 10.3390/ijms20030567. PubMed DOI PMC

Noguer-Dance M., Abu-Amero S., Al-Khtib M., Lefèvre A., Coullin P., Moore G.E., Cavaillé J. The primate-specific microRNA gene cluster (C19MC) is imprinted in the placenta. Hum. Mol. Genet. 2010;19:3566–3582. doi: 10.1093/hmg/ddq272. PubMed DOI

Augello C., Vaira V., Caruso L., Destro A., Maggioni M., Park Y.N., Montorsi M., Santambrogio R., Roncalli M., Bosari S. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 2012;32:772–782. doi: 10.1111/j.1478-3231.2012.02795.x. PubMed DOI

Flor I., Bullerdiek J. The dark side of a success story: microRNAs of the C19MC cluster in human tumours. J. Pathol. 2012;227:270–274. doi: 10.1002/path.4014. PubMed DOI

Vaira V., Elli F., Forno I., Guarnieri V., Verdelli C., Ferrero S., Scillitani A., Vicentini L., Cetani F., Mantovani G., et al. The microRNA cluster C19MC is deregulated in parathyroid tumours. J. Mol. Endocrinol. 2012;49:115–124. doi: 10.1530/JME-11-0189. PubMed DOI

Rippe V., Dittberner L., Lorenz V.N., Drieschner N., Nimzyk R., Sendt W., Junker K., Belge G., Bullerdiek J. The two stem cell microRNA gene clusters C19MC and miR-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas. PLoS ONE. 2015;5:e9485. doi: 10.1371/journal.pone.0009485. PubMed DOI PMC

Kotlabova K., Doucha J., Hromadnikova I. Placental-specific microRNA in maternal circulation—Identification of appropriate pregnancy-associated microRNAs with diagnostic potential. J. Reprod. Immunol. 2011;89:185–191. doi: 10.1016/j.jri.2011.02.006. PubMed DOI

Hromadnikova I. Extracellular nucleic acids in maternal circulation as potential biomarkers for placental insufficiency. DNA Cell Biol. 2012;31:1221–1232. doi: 10.1089/dna.2011.1530. PubMed DOI PMC

Devor E., Santillan D., Scroggins S., Warrier A., Santillan M. Trimester-specific plasma exosome microRNA expression profiles in preeclampsia. J. Matern. Fetal Neonatal Med. 2019;30:1–9. doi: 10.1080/14767058.2019.1569614. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Ondrackova M., Pirkova P., Kestlerova A., Novotna V., Hympanova L., Krofta L. Expression profile of C19MC microRNAs in placental tissue in pregnancy-related complications. DNA Cell Biol. 2015;34:437–457. doi: 10.1089/dna.2014.2687. PubMed DOI PMC

Roberge S., Bujold E., Nicolaides K.H. Aspirin for the prevention of preterm and term preeclampsia: Systematic review and metaanalysis. Am. J. Obstet. Gynecol. 2018;218:287–293. doi: 10.1016/j.ajog.2017.11.561. PubMed DOI

Zhu J., Huang R., Zhang J., Ye W., Zhang J. A prophylactic low-dose aspirin earlier than 12 weeks until delivery should be considered to prevent preeclampsia. Med. Hypotheses. 2018;121:127–130. doi: 10.1016/j.mehy.2018.08.005. PubMed DOI

Wright D., Rolnik D.L., Syngelaki A., de Paco Matallana C., Machuca M., de Alvarado M., Mastrodima S., Tan M.Y., Shearing S., Persico N., et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: Effect of aspirin on length of stay in the neonatal intensive care unit. Am. J. Obstet. 2018;218:612.e1–612.e6. doi: 10.1016/j.ajog.2018.02.014. PubMed DOI

Vayssière C., Sentilhes L., Ego A., Bernard C., Cambourieu D., Flamant C., Gascoin G., Gaudineau A., Grangé G., Houfflin-Debarge V., et al. Fetal growth restriction and intra-uterine growth restriction: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians. Eur. J. Obstet. Gynecol. Reprod. Biol. 2015;193:10–18. doi: 10.1016/j.ejogrb.2015.06.021. PubMed DOI

Nawathe A., David A.L. Prophylaxis and treatment of foetal growth restriction. Best Pract. Res. Clin. Obstet. Gynaecol. 2018;49:66–78. doi: 10.1016/j.bpobgyn.2018.02.007. PubMed DOI

Groom K.M., David A.L. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am. J. Obstet. Gynecol. 2018;218:S829–S840. doi: 10.1016/j.ajog.2017.11.565. PubMed DOI

Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol. 2000;183:S1–S22. doi: 10.1067/mob.2000.107928. PubMed DOI

Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. American College of Obstetricians and Gynecologists. Obstet. Gynecol. 2002;99:159–167. PubMed

American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 2013;122:1122–1131. PubMed

American College of Obstetricians and Gynecologists ACOG Practice bulletin no. 134: Fetal growth restriction. Obstet. Gynecol. 2013;121:1122–1133. doi: 10.1097/01.AOG.0000429658.85846.f9. PubMed DOI

Cnossen J.S., Morris R.K., ter Riet G., Mol B.W., van der Post J.A., Coomarasamy A., Zwinderman A.H., Robson S.C., Bindels P.J., Kleijnen J., et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: A systematic review and bivariable meta-analysis. Cmaj. 2008;178:701–711. doi: 10.1503/cmaj.070430. PubMed DOI PMC

Society for Maternal-Fetal Medicine Publications Committee. Berkley E., Chauhan S.P., Abuhamad A. Doppler assessment of the fetus with intrauterine growth restriction. Am. J. Obstet. Gynecol. 2012;206:300–308. doi: 10.1016/j.ajog.2012.01.022. Erratum in Am. J. Obstet. Gynecol.2015, 212, 246. Am. J. Obstet. Gynecol.2012, 206, 508. PubMed DOI

Gramellini D., Folli M.C., Raboni S., Vadora E., Merialdi A. Cerebral-umbilical Doppler ratio as a predictor of adverse perinatal outcome. Obstet. Gynecol. 1992;74:416–420. doi: 10.1097/00006250-199203000-00018. PubMed DOI

Arias F. Accuracy of the middle-cerebral-to-umbilical-artery resistance index ratios in the prediction of neonatal outcome in patients at high risk for fetal and neonatal complications. Am. J. Obstet. Gynecol. 1994;171:1541–1545. doi: 10.1016/0002-9378(94)90398-0. PubMed DOI

Arbeille P., Maulik D., Fignon A., Stale H., Berson M., Bodard S., Locatelli A. Assessment of the fetal pO2 changes by cerebral and umbilical Doppler on lamb fetuses during acute hypoxia. Ultrasound Med. Biol. 1995;21:861–870. doi: 10.1016/0301-5629(95)00025-M. PubMed DOI

Bahado-Singh R.O., Kovanci E., Jeffres A., Oz U., Deren O., Copel J., Mari G. The Doppler cerebroplacental ratio and perinatal outcome in intrauterine growth restriction. Am. J. Obstet. Gynecol. 1999;180:750–756. doi: 10.1016/S0002-9378(99)70283-8. PubMed DOI

Fleischer A., Schulman H., Farmakides G., Bracero L., Blattner P., Randolph G. Umbilical artery velocity waveforms and intrauterine growth retardation. Am. J. Obstet. Gynecol. 1985;151:502–506. doi: 10.1016/0002-9378(85)90278-9. PubMed DOI

Soregaroli M., Bonera R., Danti L., Dinolfo D., Taddei F., Valcamonico A., Frusca T. Prognostic role of umbilical artery Doppler velocimetry in growth-restricted fetuses. J. Matern. Fetal Neonatal Med. 2002;11:199–203. doi: 10.1080/jmf.11.3.199.203. PubMed DOI

Baschat A.A., Gembruch U., Weiner C.P., Harman C.R. Qualitative venous Doppler waveform analysis improves prediction of critical perinatal outcomes in premature growth-restricted fetuses. Ultrasound Obstet. Gynecol. 2003;22:240–245. doi: 10.1002/uog.149. PubMed DOI

Seravalli V., Baschat A.A. A uniform management approach to optimize outcome in fetal growth restriction. Obstet. Gynecol. Clin. N. Am. 2015;42:275–288. doi: 10.1016/j.ogc.2015.01.005. PubMed DOI

Thaler I., Weiner Z., Itskovitz J. Systolic or diastolic notch in uterine artery blood flow velocity waveforms in hypertensive pregnant patients: Relationship to outcome. Obstet. Gynecol. 1992;80:277–282. PubMed

Park Y.W., Cho J.S., Kim H.S., Kim J.S., Song C.H. The clinical implications of early diastolic notch in third trimester Doppler waveform analysis of the uterine artery. J. Ultrasound Med. 1996;15:47–51. doi: 10.7863/jum.1996.15.1.47. PubMed DOI

Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

First-Trimester Screening for Fetal Growth Restriction and Small-for-Gestational-Age Pregnancies without Preeclampsia Using Cardiovascular Disease-Associated MicroRNA Biomarkers

Cardiovascular Disease-Associated MicroRNA Dysregulation during the First Trimester of Gestation in Women with Chronic Hypertension and Normotensive Women Subsequently Developing Gestational Hypertension or Preeclampsia with or without Fetal Growth Restriction